Previous Article | Next Article 
Journal of Virology, July 2000, p. 5911-5920, Vol. 74, No. 13
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The Core of the Respiratory Syncytial Virus Fusion
Protein Is a Trimeric Coiled Coil
Jacqueline M.
Matthews,1,*
Thomas F.
Young,1
Simon P.
Tucker,2 and
Joel P.
Mackay1
Department of Biochemistry, University of
Sydney, Sydney, New South Wales 2006,1 and
Biota Holdings Ltd., Melbourne, Victoria
3004,2 Australia
Received 10 January 2000/Accepted 6 April 2000
 |
ABSTRACT |
Entry into the host cell by enveloped viruses is mediated by fusion
(F) or transmembrane glycoproteins. Many of these proteins share a fold
comprising a trimer of antiparallel coiled-coil heterodimers, where the
heterodimers are formed by two discontinuous heptad repeat motifs
within the proteolytically processed chain. The F protein of human
respiratory syncytial virus (RSV; the major cause of lower respiratory
tract infections in infants) contains two corresponding regions that
are predicted to form coiled coils (HR1 and HR2), together with a third
predicted heptad repeat (HR3) located in a nonhomologous position. In
order to probe the structures of these three domains and ascertain the
nature of the interactions between them, we have studied the isolated
HR1, HR2, and HR3 domains of RSV F by using a range of biophysical
techniques, including circular dichroism, nuclear magnetic resonance
spectroscopy, and sedimentation equilibrium. HR1 forms a symmetrical,
trimeric coiled coil in solution (K3
2.2 × 1011 M
2) which interacts with HR2
to form a 3:3 hexamer. The HR1-HR2 interaction domains have been mapped
using limited proteolysis, reversed-phase high-performance liquid
chromatography, and electrospray-mass spectrometry. HR2 in isolation
exists as a largely unstructured monomer, although it exhibits a
tendency to form aggregates with
-sheet-like characteristics. Only a
small increase in
-helical content was observed upon the formation
of the hexamer. This suggests that the RSV F glycoprotein contains a
domain that closely resembles the core structure of the simian
parainfluenza virus 5 fusion protein (K. A. Baker, R. E. Dutch, R. A. Lamb, and T. S. Jardetzky, Mol. Cell 3:309-319,
1999). Finally, HR3 forms weak
-helical homodimers that do not
appear to interact with HR1, HR2, or the HR1-HR2 complex. The results
of these studies support the idea that viral fusion proteins have a
common core architecture.
 |
INTRODUCTION |
Human respiratory syncytial virus
(RSV) is an important cause of lower respiratory tract infections in
infants, the elderly, and immunocompromised individuals. RSV is an
enveloped virus with three transmembrane surface proteins, G, F, and
SH. While all of these proteins are reported to be required for
efficient fusion (26), the F (or fusion) glycoprotein is
thought to be the major mediator of this event (33). Indeed,
F is the only surface protein that is essential for viral replication
in vitro and in vivo (5, 56, 60). F shares many features
with homologous proteins in other paramyxoviruses (reviewed in
reference 36). It is a type I glycoprotein that
becomes active only after intracellular proteolytic cleavage, forming
two disulfide-linked subunits, F1 and F2. The newly formed N terminus of F1 is believed to be the fusion
peptide, and this sequence is separated from a transmembrane domain by ~375 residues. Immediately adjacent to the fusion peptide and the
transmembrane domains (see Fig. 1) are two heptad repeat (HR) regions,
HR1 and HR2, respectively. All of these features are common in other
fusion-mediating proteins of enveloped viruses.
A number of mutational studies have shown that the HR regions HR1 and
HR2 are necessary for viral fusion (4, 12, 14, 49). Although
their precise role in fusion is not yet known, structural studies on
fragments from a range of viral fusion or transmembrane proteins have
shown that these regions have a common, structurally important role.
The structures of gp41 from simian immunodeficiency virus (SIV) and
human immunodeficiency virus (HIV) (7, 10, 40, 55, 59),
hemagglutinin (HA) from influenza A (6, 63), F from simian
virus 5 (SV5 [1]), TM from Moloney murine leukemia
virus (17), GP2 from Ebola virus (41, 58), gp21
from human T-cell leukemia virus type 1 (35), and HEF of
influenza C virus (51) are all trimeric, centered around a
trimeric coiled coil of the three HR1 regions. In some of these
structures (e.g., gp41, HA, SV5 F, and Gp2), the HR2 region is resolved
as a second layer of helices that packs in an antiparallel manner
against the trimeric HR1 coiled coil.
Arguably, the best model for the mechanism of action of a fusion
protein comes from studies of HA (for a recent review, see reference
13) for which structures of both a low pH (fusogenic [6]) and neutral pH (nonfusogenic
[63]) form have been solved. These different forms
have different conformations, suggesting that fusion is mediated by a
conformational transition that occurs when a metastable neutral pH form
of HA encounters the acidic environment in which fusion takes place.
Although compelling analogies have been made on the basis of structural
similarities between fusion proteins (see, for example, reference
10), it is not yet clear whether similar
"spring-loaded" mechanisms are utilized by other viruses.
There is some evidence to suggest that HR regions from some
paramyxovirus F proteins can associate with lipids, suggesting that
these regions, while playing a structural role, might also assist in
the fusion mechanism by binding to the membrane of target cells
(2, 22, 44). Given that the HR regions form amphipathic helices in solution, and that these structures have a general tendency
to bind lipids, such observations are perhaps not surprising; it
remains to be confirmed whether this activity has biological significance in the case of the HR peptides.
Peptides corresponding to some of these HR regions have been found to
specifically inhibit viral fusion and/or infection in vitro (27,
28, 37, 48, 61, 62, 67-69). Furthermore, it has been shown that
a peptide (known as T-20 or DP-178) corresponding to the HR1 region of
gp41 is safe and provides potent inhibition of HIV replication when
injected into human patients (34). While these peptides
could potentially bind to the lipid bilayer, host cell proteins, or
various sites on the viral transmembrane proteins, a commonly invoked
model involves direct binding to the complementary HR region in an
intermediate form of the F glycoprotein (see, for example, reference
19). This model for inhibition is consistent with
proposed mechanisms of fusion that involve changes in conformation of
the F protein (see reference 1 and references
therein). There is compelling evidence that the peptides and their
synthetic analogues act in a dominant negative manner and inhibit
fusion through interference with the intramolecular HR1 and HR2
interaction required for formation of the hexamer (see references
16, 18, 19, and 50 and references therein).
In RSV F, the positions of HR1 and HR2 are homologous to those found in
all identified fusion proteins. HR1 (corresponding to the "core"
peptide) lies immediately adjacent to the putative fusion peptide at
the N terminus of F1. HR2 lies adjacent to the predicted
transmembrane region of F1. A third heptad region, HR3, is
predicted to form in the F2 subunit of F (37).
Note that HR3 is not expected to correspond to putative leucine zipper
regions that have been identified between the HR1 and HR2 regions in
the F1 subunit of a number of other paramyxoviruses,
including Sendai virus, rinderpest, measles, parainfluenza, and SV5
(20). The role of HR3 in RSV F has yet to be identified, and
although HR2 has been shown to inhibit viral fusion (37),
its mode of action and whether it interacts with HR1 and/or with HR3
have not yet been established.
In this paper, we have attempted to address these deficiencies. We have
produced recombinant peptides corresponding to HR1, HR2, and HR3 and
have studied their conformations and their ability to form stable
complexes with themselves and with each other. We show that HR1 does
form a helical trimer and that this trimer interacts with monomeric HR2
to form a hexameric complex that we believe to be the core of a fusion
active trimeric F protein. HR3 does not appear to interact with HR1,
HR2, or the HR1-HR2 hexamer, and instead, it is anticipated to have an
independent structural role.
 |
MATERIALS AND METHODS |
Production of HR1-HR2 peptides.
Synthetic genes were
constructed for the production of recombinant HR1, HR2, and HR3.
Oligonucleotides (~70 bases; Gibco Life Sciences) with overlaps of 20 bp were designed such that they corresponded to the amino acid
sequences of HR1, HR2, and HR3. HR2 contains an additional nonviral
C-terminal tyrosine residue to enable detection of the peptide at 280 nm. Codon usage reflected that of highly expressed Escherichia
coli genes.
The synthetic genes were generated in a single step using PCR and were
further amplified using PCR. These inserts were then cloned, via
BamHI and EcoRI restriction sites, into the
E. coli expression vector pGEX-2T (Pharmacia), creating
C-terminal fusions with glutathione-S-transferase (GST). The
GST fusion proteins were expressed in the host strain BL21(DE3) grown
in Luria broth. Cells were grown at 25 or 37°C, and expression of the
recombinant proteins was induced at an A600 of
between 0.6 and 0.8 by the addition of
isopropyl-
-D-thiogalactoside (0.1 to 0.4 mM). After a
further 3 to 4 h, cells were harvested by centrifugation and stored at
80°C. In the case of 15N-labelled HR1, cells
were grown in minimal media containing 15N-labelled
NH4Cl as the sole nitrogen source, according to the method
of Cai et al. (8).
Cell pellets were resuspended in lysis buffer containing Tris-HCl (50 mM, pH 8), EDTA (1 mM), NaCl (150 mM), phenylmethylsulfonyl
fluoride
(0.5 µM), and

-mercaptoethanol (2 mM). The suspension
was
incubated on ice for 30 min, treated with Triton X-100 to
1%, and
further incubated on ice for 30 min. Cells were lysed
by sonication and
pelleted by centrifugation. The supernatant
was loaded onto an
S-hexylglutathione column (Pharmacia) preequilibrated
in
phosphate-buffered saline (PBS) (20 mM NaH
2PO
4,
150 mM NaCl,
pH 7.4) containing 1 mM EDTA and 0.5 µM
phenylmethylsulfonyl fluoride.
The column was washed, and the
recombinant peptides were cleaved
from the column with thrombin (20 U
per 1-liter culture) at 37°C
for 1 h. The eluted peptides were
purified to homogeneity by reversed-phase
high-performance liquid
chromatography (HPLC), and their identity
was confirmed using
electrospray-mass spectrometry (ES-MS). Molar
extinction coefficients
were estimated using the method described
by Gill and von Hippel
(
23).
Preparation of HR3-IAM.
HR3 peptide was dissolved in a
solution containing 0.5 M Tris-HCl (pH 8.0), 1 mM EDTA, 6 M GdnHCl, and
5 mM dithiothreitol, and the solution was incubated at room temperature
for 2 h in order to fully reduce any disulfide bonds. Reduced HR3
was then treated with 20 mM iodoacetamide for 40 min at room
temperature in the dark, and the alkylation reaction was quenched by
the addition of excess
-mercaptoethanol. The modified peptide was
desalted and purified by reversed-phase HPLC using a Waters radial
compression semipreparative column and a linear
acetonitrile-trifluoroacetic acid gradient. The mass of the modified
peptide corresponded to the addition of a single acetamide group.
CD spectropolarimetry.
Circular dichroism (CD) spectra were
recorded on a Jasco J-720 spectropolarimeter over the wavelength range
of 184 to 260 nm with a resolution of 0.5 nm and a bandwidth of 1 nm.
The temperature was maintained at 25°C using a water-jacketed cell
holder. Final spectra were the sums of three to five scans accumulated
at a speed of 20 nm min
1 with a response time of 1 s
and were baseline corrected. Path lengths were 0.1, 1, or 10 mm for
>50 µM, 20 to 50 µM, or <20 µM solutions, respectively.
Peptide samples (10 to 20 µM) were prepared by dissolving each
peptide in water and then adding 20 mM NaH
2PO
4
(pH 6.0 or 7.4)
either with or without 150 mM NaCl. The proportions of
different
secondary structural elements were predicted using the
programs
Prosec (Aviv; with reference to the standard spectra of Yang
et
al. [
66]) and CDsstr (
30).
Analytical ultracentrifugation.
Sedimentation equilibrium
experiments were carried out at 25°C using a Beckman Optima XL-A
ultracentrifuge equipped with an Anti-60 rotor. Samples were either
dialyzed against PBS (20 mM NaH2PO4, pH 7.4, 150 mM NaCl) or were passed through an analytical gel filtration column
(Superdex Peptide PC 3.2/30; Pharmacia) using PBS as a buffer and at a
flow rate of 50 to 100 µl/min. Samples were prepared at three
different protein concentrations (by serial dilution) so that they had
absorbances at 280 or 230 nm of ~1.0, 0.3, and 0.1 (in
1.2-cm-path-length cells). Data were recorded at three different speeds
in double-sector cells as absorbance-versus-radius scans (0.001-cm
increments, 10 scans). Scans were collected at intervals of 3 h and
compared to ensure that the sample reached equilibrium. Analysis of the
data was carried out using the NONLIN (29) and OMMENU
(47) software, and the final parameters were determined by a
nonlinear least-squares fit to models incorporating either a single,
nonassociating species or a reversible oligomerization reaction. The
goodness-of-fit was determined by examination of the
2
values and the residuals derived from the fit. The partial specific volume of each peptide was calculated from the amino acid sequence using the program SEDNTERP (25), and the solvent density was calculated from tabulated values for each major solution component.
1H NMR spectroscopy.
Peptides were dissolved in
a solution (0.55 ml) containing a 95:5 ratio of H2O to
D2O and 20 µM
d4-(trimethylsilyl)propionic acid
(d4-TSP) and adjusted to pH 5.5 using 0.1 M
NaOH. Nuclear magnetic resonance (NMR) spectra were recorded at 25°C
on a Bruker DRX600 equipped with a triple resonance (HCN) probe and
three-axis pulsed-field gradients. One-dimensional 1H data
were acquired with 16K complex data points and 64 to 128 scans and over
a spectral width of 7,200 Hz. The solvent signal was suppressed using a
WATERGATE sequence (45) immediately prior to data
acquisition. 15N-HSQC (43) and HNHA
(57) experiments were recorded using published sequences.
All spectra were acquired with spectral widths of 1,800 and 7,200 Hz in
the 15N and 1H dimensions, respectively.
Acquisition times of 142 ms (1H, F3), 8.9 ms
(1H, F2), and 26 ms (15N, F1) were used in the
HNHA experiment.
The data were processed by zero-filling once, linear predicting (for
indirectly acquired dimensions), and applying either
Lorentzian-Gaussian or squared shifted sine bell window functions
prior
to Fourier transformation. A polynomial baseline correction
was applied
in the directly detected dimension. The
1H frequency scale
of all spectra was directly referenced to
d4-TSP
at 0.00 ppm, while the
15N frequency scale was indirectly
referenced to liquid NH
3 by using
the method described by
Live et al. (
39).
3JHNH
coupling constants were
extracted from the HNHA spectrum
as described by Vuister and Bax
(
57).
Limited proteolysis.
Peptides were dissolved in PBS (pH 7.4)
to a final concentration of 1 mg ml
1 and were treated
with thermolysin (thermolysin-to-peptide ratio, 1:10 [wt/wt]). The
reaction was monitored using sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). Digested peptides from time points at 60 and 120 min were separated and purified using reversed-phase HPLC on a
Vydac C18 column (4.1 mm by 250 mm) with a linear
acetonitrile-trifluoroacetic acid gradient. After lyophilization, the
masses of peptides in the main peaks were determined by ES-MS on a
Finnegan LCQ mass spectrometer, using an aqueous solution of 50%
MeOH-1% acetic acid and a direct infusion rate of 3 µl
min
1.
 |
RESULTS |
Production of HR peptides.
The sequence of the F protein
(SWISS-PROT accession number P13843) of RSV (subgroup B, strain 18537)
was submitted to the program MultiCoil (65) in order to
determine whether any regions of the protein were likely to form
dimeric and trimeric coiled coils. Three such regions were identified,
all of which corresponded closely to previously identified sequences of
HR1, HR2, and HR3 regions (RSV A, strain Long [37]).
However, the details of the predictions for each of these regions
differed. HR1 was predicted to be trimeric, HR2 was weakly predicted to be either dimeric or trimeric, and HR3 was strongly predicted to be
dimeric. The score obtained for the predicted HR3 coiled coil was far
in excess of those obtained for HR1 and HR2, or any predicted
non-HR1-HR2 coiled-coil regions from all other paramyxovirus F proteins
that were subjected to this analysis (data not shown). The HR1, HR2,
and HR3 regions of RSV F and the sequences of the recombinant peptides
used in this study are shown in Fig. 1.
To increase the likelihood of the recombinant peptides forming
native-like structure, their lengths were chosen such that all residues
in each region that had a nonzero propensity to form coiled coils were
included, i.e., the peptides were designed to extend beyond the core
(underlined) sequences. It is notable that the region of HR2 that was
predicted to have the highest likelihood of forming a coiled coil (Fig.
1B, thin underline) corresponded exactly with the sequence that is
reported to most strongly inhibit syncytium formation (37).
Synthetic genes corresponding to the protein sequences of HR1, HR2, and
HR3 were assembled and subcloned into the pGEX-2T vector. The peptides
were expressed as GST fusion proteins, purified using glutathione
affinity chromatography, cleaved with thrombin, and purified to
homogeneity using reversed-phase HPLC. Note that the HR3 sequence
contains a single cysteine residue. To avoid the potential problem of
disulfide formation, a cysteine-modified form of this peptide was
generated by either iodoacetamide treatment (to form HR3-IAM) or
reduction with the reducing agent Tris(2-carboxyethyl)phosphine (TCEP).
The masses of the purified peptides were confirmed using electrospray
mass spectrometry.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
HR peptides from RSV fusion protein. (A) Schematic
diagram of the RSV F protein showing F1 and F2
and the positions of HR1, HR2, HR3, the fusion peptide (FP), and the
transmembrane region (TM). The dashed line represents a disulfide bond.
(B) Sequences of the HR peptides used in this study. The N-terminal
Gly-Ser sequence is derived from the pGEX-2T vector. The C-terminal Tyr
residue in HR2 is nonviral and was designed to give the peptide an
absorbance at 280 nm. Predictions of coiled-coil formation are derived
from the program MultiCoil (65) and are represented as
follows: strong dimer formation (double underline), moderate trimer
formation (bold underline), and weak dimer or trimer formation (single
underline).
|
|
CD analysis of HR peptides.
Far-UV CD spectropolarimetry is a
good indicator of the type of secondary structure contained in proteins
and peptides. The far-UV CD spectrum of HR1 (Fig.
2A) exhibited minima at 208 and 222 nm,
indicating that it is predominantly
-helical (38 to 55% helical
content depending on the program used to predict secondary structure
content). The appearance of the spectrum was not affected by changes in
protein concentration in the range of 2 to 120 µM, indicating that
there were no major concentration-dependent folding transitions taking
place across this range. In contrast to HR1, HR2 appeared to be largely
unfolded, with a characteristic minimum at ~200 nm (Fig. 2B). A
shoulder was observed in the HR2 spectrum at 222 nm, suggesting the
presence of a small amount of secondary structure. The HR2 secondary
structure was predicted to be a mixture of
-helix and
-sheet by
the programs CDsstr and Prosec. Quantitation of the HR2 secondary
structure elements was not attempted due to sample-to-sample variations
and differences in output between the two programs. However, after
extended periods at room temperature or at high protein concentrations,
marked changes were observed in the HR2 spectrum (Fig. 2B). A broad
minimum appeared at ~218 nm together with a maximum at 190 nm; these
features are characteristic of
-sheet conformations, and the
secondary structure prediction software estimated a
-sheet content
of ~70%.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 2.
Far-UV CD spectra of HR1, HR2, and HR3. Shown are 20 µM HR1 (A); 20 µM HR2 normal ( ) and aged ( ) (B); and HR3-IAM
at concentrations of 1.8 µM ( ), 20 µM ( ), 33 µM ( ), and
110 µM ( ) (C). Peptides were buffered in a solution containing 150 mM sodium chloride and 20 mM sodium phosphate (pH 7.4). Spectra are the
averages of three to five scans and are baseline corrected.
|
|
While HR3 also appeared to be largely unfolded by far-UV CD at low
concentrations (8 to 9% helix at 2 µM), the CD spectrum
of this
peptide was strongly concentration dependent. The

-helical
content
of HR3-IAM was found to increase significantly at concentrations
above
20 µM, with estimates of 49 to 57%

-helix at 110 µM (Fig.
2C).
Essentially identical results were observed for HR3 in the
presence of
TCEP (HR3-TCEP; data not shown). For all peptides,
there were no
apparent differences between spectra recorded at
pHs 6.0 and 7.4 or
between spectra recorded in the presence or
absence of 150 mM NaCl
(data not
shown).
Oligomeric state of HR peptides.
Sedimentation equilibrium
experiments were carried out to determine the oligomeric states of the
HR peptides. The HR1 peptide was studied over two different
concentration ranges (with three different loading concentrations in
each case) and at three different rotor speeds. Data from the first
concentration range fitted well to a model incorporating a single,
ideal species, yielding a solution molecular mass of 18,000 Da (with
95% confidence limits of 16,900 and 19,000 Da). This value corresponds
well to that expected for a trimer of HR1, based on the amino acid
sequence (18,273 Da). The high quality of the single-species fit
suggested that HR1 was exclusively trimeric over the entire
concentration range of the experiment. Thus, in order to determine an
estimate for the trimerization constant, it was necessary to use lower
peptide loading concentrations (Fig. 3A).
Although a single-species model yielded a good fit to the nine data
sets used (Fig. 3B,
2 = 0.023), the weight-average
molecular weight obtained was lower than expected for a trimer (15,400 Da). A monomer
dimer model yielded fits to the data that were
significantly worse, as indicated by the nonrandom residuals (Fig. 3C)
and increased value of
2 (0.046). A monomer
trimer
model yielded the best fit to the data, exhibiting random residuals
(Fig. 3D), a lower value of
2 (0.021), and an
association constant of 2.2 × 1011 M
2.
Models corresponding to tetramers or higher oligomeric states yielded
poor quality fits (data not shown). An association constant of this
magnitude implies that ~90% of the peptide would be present as
trimer in a 20 µM solution (the concentration of most of the CD
experiments). Furthermore, >99% of the peptide would be present as
trimer at a peptide concentration of 1 mM (the concentration of
the NMR experiments; see below).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
HR1 is trimeric in solution. (A) A representative data
set from the sedimentation equilibrium analysis of HR1, shown as a plot
of A280 against radial position (150 mM NaCl, 20 mM NaH2PO4, pH 7.4). A total of nine data sets
were recorded and fitted globally to a range of models. A fit of the
data to a monomer trimer model is shown. Residuals from the fit of
this data set to single-species (B), monomer dimer (C), and
monomer trimer (D) models are also shown, demonstrating that the
monomer trimer model fits best to the data.
|
|
HR2 sedimentation equilibrium data recorded at loading concentrations
of 20 µM were well-fitted by a single-species model
with a solution
molecular mass of 4,710 Da (95% confidence limits
of 4,620 and 4,810 Da). This corresponds well to the theoretical
molecular mass of an HR2
monomer (4,787 Da; data not shown). At
higher concentrations, this
peptide appeared to form a large molecular
weight aggregate that
rapidly sedimented at low rotor speeds.
This observation is consistent
with results from one-dimensional
1H NMR experiments, in
which increases in protein concentration
caused a substantial
broadening of all resonances (data not
shown).
Data from the HR3 peptides HR3-IAM and HR3-TCEP fitted best to a
monomer-dimer model with a dimerization constant of ~1,300
M
1 (data not
shown).
NMR studies of HR1.
A 15N-HSQC spectrum of HR1
(Fig. 4A) revealed approximately 55 major
cross-peaks arising from backbone amide protons (in addition, cross-peak 33 probably comprises two overlapped signals). This is
consistent with the amino acid sequence from which a maximum of 57 signals would be expected (the N-terminal residue will not appear). The
relatively narrow spread of chemical shifts in the 1H
dimension is consistent with a mixture of
-helical secondary structure and random coil, as predicted from the CD data. In order to
accurately estimate the secondary structure content of the HR1 domain,
a three-dimensional HNHA spectrum (57) was recorded. From
this experiment, 3JHNH
scalar
coupling constants may be extracted for each nonoverlapped residue. The
values of these coupling constants depend on the
angle for that
residue. Thus, coupling constants of less than ~6 Hz are indicative
of
-helical secondary structure, while values greater than 8 Hz
indicate an extended
-conformation. The values of
3JHNH
are plotted against peak
number in Fig. 4B. Twenty of the 54 residues measured (peak 33 was not
used because of overlap) displayed a
3JHNH
value of <6 Hz, suggesting
that ~35% of the residues are in a helical conformation under these
conditions. This corresponds well to the lower estimates of
-helical
content from CD data. In addition, given that the HR1 peptide is
trimeric in solution, the presence of only 55 signals in the HSQC
spectrum implies that the trimer is completely symmetrical. In other
words, all of the three chains comprising the trimer adopt identical
conformations and are in the same orientation with respect to each
other.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 4.
NMR data on the HR1 domain of RSV. (A)
15N-HSQC spectrum of HR1 (1 mM, pH 5.5). Arbitrary peak
numbers are indicated on the spectrum. The side chains of Asn and Gln
residues, together with aliased signals from Arg and Lys residues, are
boxed. The inset panel shows an expansion of the most overlapped region
of the spectrum. (B) Graph of
3JHNH against peak number,
measured from the HNHA spectrum of HR1. The solid line indicates the
limiting value of 3JHNH below
which a residue is very likely to be in a helical conformation.
|
|
HR1 and HR2 form a 3:3 hexamer.
A far-UV CD spectrum of an
equimolar mixture of HR1 and HR2 was recorded. This spectrum was
compared with a theoretical spectrum obtained by summing experimental
spectra of equivalent amounts of HR1 and HR2 alone (Fig.
5A). Small but significant differences between the two spectra were observed, suggesting that secondary structure is induced by an interaction between these two peptides. Specifically, the experimental spectrum shows an increased positive signal at 195 nm (indicative of a more folded structure), an increase in the magnitude of the minimum at 222 nm, and a shift of the minimum
at 204 nm towards 208 nm; all these are characteristics of
-helical
structure. Estimates of secondary structure content indicated that
these changes correspond to an increase in
-helical content of 4 to
7%. Similarly, differences were observed between a spectrum of a
mixture of HR1 and "aged" HR2 and a summed data set created from
spectra of the individual components (Fig. 5B). In this case, an
increased maximum at 190 nm and the appearance of a double minimum at
208 and 222 nm also suggest an increase in
-helical structure,
demonstrating that HR1 is able to "rescue" the aged HR2.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 5.
The interaction of HR1 and HR2 induces the formation of
-helix. Far-UV CD spectra of HR1 with fresh HR2 (A) and with aged
HR2 (B). In both cases, experimental data ( ) and simulated data
( ) of noninteracting HR1 and HR2 are shown. (C) A representative
data set from the sedimentation equilibrium analysis of the HR1-HR2
mixture, shown as a plot of A280 against radial
position (20 mM NaH2PO4, 150 mM NaCl, pH 7.4).
A total of 11 data sets were fitted globally to a range of models. The
best fit was obtained using a single-species model, and this fit is
shown for the plotted data set. The residuals for the fit are shown in
the inset panel. Note that the scales of the main and inset panels are
different.
|
|
Solutions of HR1 and HR2 either were separately dialyzed against PBS
and mixed in a 1:1 molar ratio or were coinjected and
collected as a
single peak from an analytical gel filtration column.
These solutions
were subjected to sedimentation equilibrium analysis,
and the resulting
data were well fitted by a single-species model
(Fig.
5C) with a
solution molecular mass of 31,800 Da (with 95%
confidence limits of
29,900 and 33,800 Da). This corresponds closely
to a hexamer containing
three molecules of HR1 and three molecules
of HR2 (32,634
Da).
HR3 does not interact further with HR1, HR2, or the HR1-HR2
complex.
When HR3 peptides were mixed with HR1, HR2, or a solution
containing HR1 and HR2, far-UV CD spectra showed no change in secondary structure content (data not shown). This suggests that there is unlikely to be an interaction between HR3 and the other HR peptides. Similarly, sedimentation equilibrium experiments conducted on solutions
of HR3-IAM mixed with HR1, HR2, or HR1-HR2 gave no indication of any
additional interaction. The molecular weights obtained from fits to
single-species models corresponded to the expected weight-average
molecular weights of mixtures of monomeric HR3-IAM with trimeric HR1,
monomeric HR3-IAM with monomeric HR2, and monomeric HR3-IAM with the
hexameric HR1-HR2 complex, respectively (data not shown).
Identification of the HR1-HR2 interface.
In order to determine
which regions of HR1 and HR2 interact, the complex of these two
peptides was subjected to limited proteolysis using thermolysin.
Regions protected either by a high level of secondary structure and/or
by the formation of the HR1-HR2 hexamer were expected to be
comparatively resistant to proteolytic cleavage. Analysis by SDS-PAGE
(Fig. 6A) showed that over the course of a 1- to 2-h incubation, the band corresponding to HR1 disappeared, the
band corresponding to HR2 remained unchanged, and no significant bands
of smaller size appeared (the limit of detection by this system is
approximately 2.5 kDa). Aliquots corresponding to 60- and 120-min
incubation times were separated by reversed-phase HPLC (Fig. 6B), and
the major peaks were analyzed by ES-MS. Peptides corresponding to
full-length HR1, full-length HR2, and shorter forms of HR1 (but not
HR2) could be identified (Fig. 6C). The cleavage sites in HR1 that gave
rise to the shorter forms of the peptide were all located in the
N-terminal region, suggesting that all of HR2 and the C-terminal
residues of HR1 are involved in the HR1-HR2 interaction.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 6.
Identification of the interaction domains of HR1 and HR2
by partial thermolysin proteolysis. (A) SDS-PAGE gel showing the
following. (Top) Lane M, molecular weight markers; lane 1, thermolysin;
lane 2, HR2; lane 3, HR1; lane 4, HR1-HR2; lane 5, HR1-HR2 after 60 min
of thermolysin digestion; lane 6, HR1-HR2 after 60 min of thermolysin
digestion. (Bottom) Lane M, molecular weight markers; lane 1, HR2 at
time zero; lane 2, HR2 at 10 min; lane 3, HR1 at time zero; lane 4, HR1
at 10 min; lane 5, HR1-HR2 at 0 min; lane 6, HR1-HR2 at 10 min. (B)
Reversed-phase HPLC chromatogram of a 60-min thermolytic digest of
HR1-HR2. Peptides were identified by ES-MS from samples taken at times
indicated by a to f. (C) Sequences of peptides identified by ES-MS.
*, The major component of the peak was uncleaved HR2. No cleaved
forms of HR2 were identified.
|
|
In contrast to the results obtained with HR1-HR2 mixtures, thermolysin
treatment of solutions of HR1 and HR2 in isolation
resulted in
comparatively rapid degradation of both species (Fig.
6A). These data
support the conclusion that protection of HR1
and HR2 in the mixed
solution is due to the formation of HR1-HR2
hetero-oligomers and not
the formation of independent HR1 trimers
and/or aggregates of
HR2.
Short form of HR1.
A recombinant peptide corresponding to the
putative HR2-interacting region of HR1 (HR118-58) was also
produced. Far-UV CD analysis revealed that HR118-58 was
significantly less helical than HR1 (Fig.
7A). Data acquired from sedimentation
equilibrium experiments of HR118-58 could not be
adequately described by either a single-species model or a
monomer
trimer model, but appeared to be aggregating in a nonspecific
manner (data not shown).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 7.
Far-UV CD spectra of HR118-58. Far-UV CD
spectra of HR118-58 ( ) (A) and an equimolar mixture of
experimental data ( ) (B). Also shown in panel B is a simulated
spectrum of noninteracting HR118-58 and HR2 ( ). Total
protein concentrations were 20 µM in each case. Peptides were
buffered in 20 mM NaH2PO4, 150 mM NaCl (pH
7.4). Spectra are the average of three to five scans and are baseline
corrected.
|
|
When a solution containing equimolar amounts of HR2 and
HR1
18-58 was analyzed by far-UV CD, a small increase in

-helical
content (4 to 15%) was observed (Fig.
7B). In addition,
sedimentation
equilibrium analysis of a mixture of HR2 and
HR1
18-58 revealed
an increase of the weight-average
molecular weight of the mixture
over the weight-average molecular
weight of HR1
18-58 alone
(data not shown). Taken together,
these observations suggest that
HR1
18-58 and HR2 interact,
although the nature of the interaction
could not be clearly defined due
to the self-association of HR1
18-58.
 |
DISCUSSION |
The striking similarities in gross structural features of
viral fusion proteins are suggestive of similar mechanisms of action and have led to speculation of common ancestry (1, 9, 51, 58). One of the most conserved of these features is an HR that forms a trimeric coiled-coil core (termed here the HR1 region) arranged
along the central axis of the fusion protein and perpendicular to the
viral membrane. The data presented here demonstrate that the
corresponding region of the RSV fusion protein (HR1) forms a
symmetrical trimer that contains a significant amount of
-helix.
The
-helical content of HR1 is estimated to be ~35% from NMR
scalar coupling measurements and using the CD secondary structure prediction program Prosec. This equates to ~20 residues existing in
an
-helical conformation and is comparable to the level of 47%
helical content reported for a slightly larger peptide corresponding to
the HR1 region of a related paramyxovirus, SV5 (31). Both estimates of helical content are low compared with NMR studies in which
the Newcastle disease virus (NDV) HR1 peptide was shown to be monomeric
and highly helical (69). However, it should be noted that a
much shorter peptide (23 amino acids) was used in the latter studies
and that the experiments were carried out in the presence of SDS
micelles, which are known to promote
-helical content in peptides
that correspond to amphipathic helices in proteins.
Although 20 amino acids constitute a relatively small
-helix in
comparison to published HR1 structures, it is reasonable to expect a
proportion of random coil in these peptides given that they are
isolated peptides and thus likely to have frayed ends. The trimming of
HR1 by proteolysis of the HR1-HR2 complex residues (Fig. 6) also
suggests that not all of the HR1 region in the peptide studied is
involved in coiled-coil formation. In light of these results, we
expected that the proteolytically clipped form of HR1
(HR118-58) would be correspondingly more helical, although
this was not the case. Instead, HR118-58 was significantly less helical, showed a tendency to self-associate nonspecifically, and
displayed only limited evidence of interaction with HR2. These data are
consistent with the results of Lamb and colleagues (31), who
have reported that the trimming of eight residues from the N terminus
of the HR1 peptide of a related paramyxovirus, SV5, virtually halved
the
-helical character of that peptide. The untrimmed SV5 peptide
used in their subsequent studies was slightly larger than our
full-length HR1 peptide and included two hydrophobic residues that have
been subsequently shown to form part of a nonpredicted, stuttered
3-4-4-4-3 HR at the C terminus of the SV5 coiled-coil (1).
Pneumovirus F sequence alignments (not shown) also show conservation of
a hydrophobic amino acid equivalent to the penultimate residue in our
HR1 sequence (corresponding to I180 in SV5 and V207 in human RSV),
supporting the proposal that the RSV coiled coil adopts a comparable
structure (1). If so, the absence of the complete C-terminal
turn in our HR1 peptide may also contribute to the slightly
lower-than-expected
-helical content in the untrimmed peptide.
We also examined a C-terminally truncated form of HR1 lacking seven
residues that were removed by thrombin cleavage as part of the
purification process (data not shown). This peptide, although still
maintaining helical character, was significantly less helical than HR1
(data not shown). Such decreases in helical character may result from
the elimination of key residues that specifically direct trimer
formation. In general, the HR1 regions are irregular, containing a high
proportion of hydrophobic residues apart from the actual hydrophobic
repeat. These additional hydrophobic residues are involved in
interactions with HR2 regions. It has been shown that the buried core
residues of the HR1 region in gp41 specifically direct trimer formation
(53). Thus, it is possible that the loss of a few key
residues could reduce or eliminate such specificity, and the high
proportion of hydrophobic residues remaining in HR118-58 could cause nonspecific aggregation, preventing helical formation. Using sedimentation equilibrium experiments, the association constant of trimerization was estimated to be 2.2 × 1011
M
2. This is essentially identical to estimates of
1.5 × 1011 M
2 for SIV e-gp41
(7) and 4.5 × 1011 M
2 for
HIV e-gp41 (64), constructs which contain both the HR1 and
the HR2 regions as well as the intervening residues of gp41. Given that
our estimate of the HR1 association constant does not account for any
contribution by HR2, we would expect the association constant for an
equivalent construct of the RSV F protein to be significantly larger.
The formation of a trimer by HR1 is consistent with cross-linking
studies of RSV F (52). However, sedimentation equilibrium studies of the HR1 peptide from gp41 suggested that this peptide underwent a monomer
dimer
tetramer association (38).
This observation is consistent with earlier reports for isolated gp41
HR1 peptide and peptide-fusion protein constructs (3, 46,
54) as well as whole-protein studies (see reference
42 and references therein), but is in conflict with
later observations of the trimer core (7, 55, 59, 64). These
discrepancies may be partially attributable to the susceptibility of
differing techniques to artifact (e.g., see reference
3), and in addition, it is notable that the HR1
peptide sequences used by various groups were not identical. The
propensity to form specific oligomers could be dependent on a few key
residues which differ from study to study or can be modified by other
parts of the protein (42). It is well-known that the
oligomerization specificity of coiled coils can be switched by the
mutation of even single residues (see, for example, reference
24).
The largely unstructured conformation of HR2 is a common feature of
several other HR2 peptides from other viral fusion or transmembrane
proteins (21, 37, 62). The notable exception to this is the
HR2 region from NDV, which forms helical structure with a strip of
leucine residues aligned along one face (68). The tendency
for the HR2 regions to self-associate under some conditions has also
been noted for the SV HR2 (SV-465 [21]). This property
is not surprising, given that the role of this region under native
conditions is to form part of the hydrophobic core of the F protein. It
is usually the case that both the HR1 and HR2 peptides exhibit
antiviral activity that is specific to the virus of origin, but that
the HR2 peptides are significantly more potent. However, it does not
appear to be the unstructured nature of the HR2 peptides that confers
this potency. For example, the NDV HR2 peptide is both helical and has
antiviral activity (68). In addition, a short form of the
gp41 analogue DP-178 has been forced into an
-helical conformation
through the use of one or two lactam bridges; these helical peptides
are significantly more potent than the unstructured, unmodified forms
of the same peptide (32). Because the mechanism of peptide
inhibition is not yet known, it is difficult to account for the
increased inhibitory activity of HR2 peptides. It may simply be that
only monomeric HR peptides are active, in which case the effective
concentrations of free monomer are much higher for HR2 than for HR1,
which undergoes a monomer
trimer equilibrium (7).
Alternatively, if inhibition occurs after the assembly of an F trimer,
increased potency may arise from the lower energetic cost of displacing
HR2 from a position on the outside of the HR1 trimer, compared to the
cost of complete disassembly of the trimer or hexamer (which would be
required to displace HR1).
Complex formation.
Sedimentation equilibrium data indicate
that the complex formed by HR1 and HR2 is hexameric, with a solution
molecular weight corresponding to three molecules of each peptide. This
is consistent with studies of the HR peptides from gp41 (7,
64) and the paramyxovirus F protein from SV5 (31),
although those complexes were shown to be highly helical. In this
study, the complex formed by HR1 and HR2 is apparently less helical,
despite the high affinity of the interaction (demonstrated by the
ability of HR1 to rescue aggregated HR2) (Fig. 5B). CD data suggest
that four to seven additional residues take up a helical conformation
as a result of the interaction between HR1 and HR2. This implies that
for the RSV F protein, either a core region consisting of the trimeric coiled-coil HR1 surrounded by helical HR2 is significantly shorter than
has been observed for equivalent proteins in other viruses or
additional constraints provided by other parts of the protein are
required for full helix formation. Interestingly, the structure of the
core region of the SV5 F protein shows that the HR2 domain contains
both an
-helix and an extended conformation that stretches out along
the HR2 region. Our studies demonstrate that RSV HR2 has a tendency to
adopt a
-sheet conformation and is protected from proteolysis when
in complex with HR1. Thus, it is probable that the RSV F protein core
resembles more closely that of the SV5 F protein (1) than
that of gp41 (7, 10), which has a highly helical HR2 region.
When the residues corresponding to the interacting regions of HR1 and
HR2 are superimposed onto the SV5 F structure, using the best sequence
alignment of RSV HR1 and HR2 with SV5 HR1 and HR2 (Fig.
8), they are found to correspond almost
exactly with interacting regions of the SV5 F structure. In addition,
given that there is also some variation between the reported properties
of the HR1 and HR2 peptides among the paramyxoviruses (1,
68), it may be that relatively more of the HR2 region is in an
extended conformation in the RSV F protein. While we have not yet been
able to experimentally determine the orientation of the HR2 peptides
with respect to the HR1 parallel trimer, we believe they are likely to
assume the antiparallel orientation found in most F and TM proteins
(see, for example, references 1, 6, 7, 17, and
41).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 8.
Comparison of RSV HR1 and HR2 with SV5 F. (A) Ribbon
diagram of the SV5 F structure (protein data bank identification code,
1svf [1]). HR1 regions are shown in gray, and HR2
regions are shown in black. C atoms corresponding to the
interacting regions of HR1 and HR2 are shown in CPK format. (B)
Sequence alignment of HR1 with the HR1 peptide used in the SV5
structure. (C) Sequence alignment of HR2 with the HR2 peptide used in
the SV5 structure. Identical residues are represented by dots. Residues
derived from the linker region of the GST fusion protein are in bold.
Residues corresponding to the interacting regions of HR1 and HR2 are in
italics.
|
|
Proteolysis data show that essentially all of the HR2 peptide is
protected by complex formation, while only the C-terminal
~70% of
HR1 is protected, suggesting that our original HR1 construct
extends
beyond the complexed region. This may represent a flexible
region
immediately adjacent to the fusion peptide, as is found
in HA, Ebola
virus GP2, and human T-cell leukemia virus type 1
(
11,
35,
41,
58). Alternatively, an extended form of HR1
that included the
fusion peptide might result in an extension
of the trimeric coiled-coil
core in the manner of the HIV-1 and
SV5 fusion proteins (
1,
7,
10,
55,
59).
RSV HR3 does not appear to be further involved in complex
formation.
RSV is strongly predicted to contain a third
coiled-coil region (HR3) in the F2 subunit (Fig. 2)
(37). We have shown that RSV HR3 is able to form dimeric
helices in a concentration-dependent manner, although the affinity
constant for this interaction was rather low. However, we found no
evidence to suggest that HR3 can interact with HR1, HR2, or the HR1-HR2
complex. Although HR3 does not appear to contribute to the core region
of the RSV F protein, it may have a structural role. For example,
HR3-HR3 dimerization may be involved in inter- or intramolecular
associations between or within F oligomers, respectively.
Alternatively, it may be involved in interactions with other non-HR
regions. Indeed, a cysteine residue located towards the N terminus of
HR3 (just outside the strongly predicted coiled-coil region) is likely
to connect the F2 and F1 subunits. The flanking
HR region may serve to stabilize an interaction between these two
subunits. To ensure that this cysteine residue was not itself a barrier
to HR3-core interactions, a 30-residue synthetic peptide version of
HR3, encompassing only the strongly predicted HR region, was also
investigated. This peptide similarly failed to exhibit any signs of an
interaction with the core HR peptides.
Additional HR or potential leucine zipper regions have been identified
in a number of different paramyxovirus F proteins,
most notably those
located on the F
1 subunit between the HR1 and
HR2 regions
(
15,
48). However, there are some discrepancies
regarding
their role. In the case of Sendai virus, peptides corresponding
to both
this leucine zipper and a proposed internal fusion peptide
were shown
to associate in an as yet undefined manner with biologically
active
forms of Sendai F HR1 and HR2 (
20-22,
44). However,
although
similar associations were shown between the leucine zipper
region
and HR1 and HR2 regions of SV5, it was concluded that the
leucine
zipper region did not form part of the HR1-HR2 core because no
increase in stability of the complex was observed (
15). More
detailed biophysical analysis and/or structure determination may
resolve these
discrepancies.
In conclusion, this work supports a structural theme that is emerging
for viral fusion proteins: a homotrimeric coiled-coil
core that
interacts with three complementary sequences to form
a hexamer of
heterodimers. Our data demonstrate that HR1 forms
a strong symmetrical
coiled-coil trimer that is able to form a
hexamer with HR2. A third HR
region in F
2 does not appear to be
further involved in the
formation of the F protein core. It is
likely that the structure of the
RSV F protein will be similar
in appearance to the closely related SV5
F protein, with a section
of the HR2 region forming an extended
conformation, although in
the RSV F protein this extended conformation
may comprise a larger
proportion of the HR2
region.
 |
ACKNOWLEDGMENTS |
J.M.M. is the recipient of a U2000 Fellowship. J.P.M. is the
recipient of an ARC Australian Research Fellowship.
We thank A. J. Mason and G. F. King for helpful discussions.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biochemistry, University of Sydney, Sydney, NSW 2006, Australia. Phone: 61 2 9351 6025. Fax: 61 2 9351 4726. E-mail:
j.matthews{at}biochem.usyd.edu.au.
 |
REFERENCES |
| 1.
|
Baker, K. A.,
R. E. Dutch,
R. A. Lamb, and T. S. Jardetzky.
1999.
Structural basis for paramyxovirus-mediated membrane fusion.
Mol. Cell
3:309-319[CrossRef][Medline].
|
| 2.
|
Ben-Efraim, I.,
Y. Kliger,
C. Hermesh, and Y. Shai.
1999.
Membrane-induced step in the activation of Sendai virus fusion protein.
J. Mol. Biol.
285:609-625[CrossRef][Medline].
|
| 3.
|
Bernstein, H. B.,
S. P. Tucker,
S. R. Kar,
S. A. McPherson,
D. T. McPherson,
J. W. Dubay,
J. Lebowitz,
R. W. Compans, and E. Hunter.
1995.
Oligomerization of the hydrophobic heptad repeat of gp41.
J. Virol.
69:2745-2750[Abstract].
|
| 4.
|
Buckland, R.,
E. Malvoisin,
P. Beauverger, and F. Wild.
1992.
A leucine zipper structure present in the measles virus fusion protein is not required for its tetramerization but is essential for fusion.
J. Gen. Virol.
73:1703-1707[Abstract/Free Full Text].
|
| 5.
|
Bukreyev, A.,
S. S. Whitehead,
B. R. Murphy, and P. L. Collins.
1997.
Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse.
J. Virol.
71:8973-8982[Abstract].
|
| 6.
|
Bullough, P. A.,
F. M. Hughson,
J. J. Skehel, and D. C. Wiley.
1994.
Structure of influenza haemagglutinin at the pH of membrane fusion.
Nature
371:37-43[CrossRef][Medline].
|
| 7.
|
Caffrey, M.,
M. Cai,
J. Kaufman,
S. J. Stahl,
P. T. Wingfield,
D. G. Covell,
A. M. Gronenborn, and G. M. Clore.
1998.
Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41.
EMBO J.
17:4572-4584[CrossRef][Medline].
|
| 8.
|
Cai, M.,
Y. Huang,
K. Sakaguchi,
G. Clore,
A. Gronenborn, and R. Craigie.
1998.
An efficient and cost-effective isotope labelling protocol for labelling protein expressed in Escherichia coli.
J. Biomol. NMR
11:97-102[CrossRef][Medline].
|
| 9.
|
Chambers, P.,
C. R. Pringle, and A. J. Easton.
1990.
Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins.
J. Gen. Virol.
71:3075-3080[Abstract/Free Full Text].
|
| 10.
|
Chan, D. C.,
D. Fass,
J. M. Berger, and P. S. Kim.
1997.
Core structure of gp41 from the HIV envelope glycoprotein.
Cell
89:263-273[CrossRef][Medline].
|
| 11.
|
Chen, J.,
J. J. Skehel, and D. C. Wiley.
1999.
N- and C-terminal residues combine in the fusion-pH influenza hemagglutinin HA(2) subunit to form an N cap that terminates the triple-stranded coiled coil.
Proc. Natl. Acad. Sci. USA
96:8967-8972[Abstract/Free Full Text].
|
| 12.
|
Chen, S. S.,
C. N. Lee,
W. R. Lee,
K. McIntosh, and T. H. Lee.
1993.
Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein.
J. Virol.
67:3615-3619[Abstract/Free Full Text].
|
| 13.
|
Chernomordik, L. V.,
E. Leikina,
M. M. Kozlov,
V. A. Frolov, and J. Zimmerberg.
1999.
Structural intermediates in influenza haemagglutinin-mediated fusion.
Mol. Membr. Biol.
16:33-42[CrossRef][Medline].
|
| 14.
|
Dubay, J. W.,
S. J. Roberts,
B. Brody, and E. Hunter.
1992.
Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity.
J. Virol.
66:4748-4756[Abstract/Free Full Text].
|
| 15.
|
Dutch, R. E.,
G. P. Leser, and R. A. Lamb.
1999.
Paramyxovirus fusion protein: characterization of the core trimer, a rod-shaped complex with helices in anti-parallel orientation.
Virology
254:147-159[CrossRef][Medline].
|
| 16.
|
Eckert, D. M.,
V. N. Malashkevich,
L. H. Hong,
P. A. Carr, and P. S. Kim.
1999.
Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.
Cell
99:103-115[CrossRef][Medline].
|
| 17.
|
Fass, D.,
S. C. Harrison, and P. S. Kim.
1996.
Retrovirus envelope domain at 1.7 angstrom resolution.
Nat. Struct. Biol.
3:465-469[CrossRef][Medline].
|
| 18.
|
Ferrer, M.,
T. M. Kapoor,
T. Strassmaier,
W. Weissenhorn,
J. J. Skehel,
D. Oprian,
S. L. Schreiber,
D. C. Wiley, and S. C. Harrison.
1999.
Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
Nat. Struct. Biol.
6:953-960[CrossRef][Medline].
|
| 19.
|
Furuta, R. A.,
C. T. Wild,
Y. Weng, and C. D. Weiss.
1998.
Capture of an early fusion-active conformation of HIV-1 gp41.
Nat. Struct. Biol.
5:276-279[CrossRef][Medline].
|
| 20.
|
Ghosh, J. K.,
M. Ovadia, and Y. Shai.
1997.
A leucine zipper motif in the ectodomain of Sendai virus fusion protein assembles in solution and in membranes and specifically binds biologically-active peptides and the virus.
Biochemistry
36:15451-15462[CrossRef][Medline].
|
| 21.
|
Ghosh, J. K.,
S. G. Peisajovich,
M. Ovadia, and Y. Shai.
1998.
Structure-function study of a heptad repeat positioned near the transmembrane domain of Sendai virus fusion protein which blocks virus-cell fusion.
J. Biol. Chem.
273:27182-27190[Abstract/Free Full Text].
|
| 22.
|
Ghosh, J. K., and Y. Shai.
1999.
Direct evidence that the N-terminal heptad repeat of Sendai virus fusion protein participates in membrane fusion.
J. Mol. Biol.
292:531-546[CrossRef][Medline].
|
| 23.
|
Gill, S. C., and P. H. von Hippel.
1989.
Calculation of protein extinction coefficients from amino acid sequence data.
Anal. Biochem.
182:319-326[CrossRef][Medline].
|
| 24.
|
Gonzalez, L., Jr.,
D. N. Woolfson, and T. Alber.
1996.
Buried polar residues and structural specificity in the GCN4 leucine zipper.
Nat. Struct. Biol.
3:1011-1018[CrossRef][Medline].
|
| 25.
|
Hayes, D. B.,
T. Laue, and J. Philo.
1995.
SEDNTERP.
University of New Hampshire, Durham.
|
| 26.
|
Heminway, B. R.,
Y. Yu,
Y. Tanaka,
K. G. Perrine,
E. Gustafson,
J. M. Bernstein, and M. S. Galinski.
1994.
Analysis of respiratory syncytial virus F, G, and SH proteins in cell fusion.
Virology
200:801-805[CrossRef][Medline].
|
| 27.
|
Jiang, S.,
K. Lin,
N. Strick, and A. R. Neurath.
1993.
HIV-1 inhibition by a peptide.
Nature
365:113[Medline].
|
| 28.
|
Jiang, S.,
K. Lin,
N. Strick, and A. R. Neurath.
1993.
Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41.
Biochem. Biophys. Res. Commun.
195:533-538[CrossRef][Medline].
|
| 29.
|
Johnson, M. L.,
J. J. Correia,
D. A. Yphantis, and H. R. Halvorson.
1981.
Analysis of data from the analytical ultracentrifuge by nonlinear least-squares techniques.
Biophys. J.
36:575-588[Medline].
|
| 30.
|
Johnson, W. C.
1999.
Analyzing protein circular dichroism spectra for accurate secondary structures.
Proteins
35:307-312[CrossRef][Medline].
|
| 31.
|
Joshi, S. B.,
R. E. Dutch, and R. A. Lamb.
1998.
A core trimer of the paramyxovirus fusion protein: parallels to influenza virus hemagglutinin and HIV-1 gp41.
Virology
248:20-34[CrossRef][Medline].
|
| 32.
|
Judice, J. K.,
J. Y. Tom,
W. Huang,
T. Wrin,
J. Vennari,
C. J. Petropoulos, and R. S. McDowell.
1997.
Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism.
Proc. Natl. Acad. Sci. USA
94:13426-13430[Abstract/Free Full Text].
|
| 33.
|
Kahn, J. S.,
M. J. Schnell,
L. Buonocore, and J. K. Rose.
1999.
Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion.
Virology
254:81-91[CrossRef][Medline].
|
| 34.
|
Kilby, J. M.,
S. Hopkins,
T. M. Venetta,
B. DiMassimo,
G. A. Cloud,
J. Y. Lee,
L. Alldredge,
E. Hunter,
D. Lambert,
D. Bolognesi,
T. Matthews,
M. R. Johnson,
M. A. Nowak,
G. M. Shaw, and M. S. Saag.
1998.
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.
Nat. Med.
4:1302-1307[CrossRef][Medline].
|
| 35.
|
Kobe, B.,
R. J. Center,
B. E. Kemp, and P. Poumbourios.
1999.
Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins.
Proc. Natl. Acad. Sci. USA
96:4319-4324[Abstract/Free Full Text].
|
| 36.
|
Lamb, R. A.
1993.
Paramyxovirus fusion: a hypothesis for changes.
Virology
197:1-11[CrossRef][Medline].
|
| 37.
|
Lambert, D. M.,
S. Barney,
A. L. Lambert,
K. Guthrie,
R. Medinas,
D. E. Davis,
T. Bucy,
J. Erickson,
G. Merutka, and S. R. Petteway, Jr.
1996.
Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.
Proc. Natl. Acad. Sci. USA
93:2186-2191[Abstract/Free Full Text].
|
| 38.
|
Lawless, M. K.,
S. Barney,
K. I. Guthrie,
T. B. Bucy,
S. R. Petteway, Jr., and G. Merutka.
1996.
HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.
Biochemistry
35:13697-13708[CrossRef][Medline].
|
| 39.
|
Live, D. H.,
D. G. Davis,
W. C. Agosta, and D. Cowburn.
1984.
Long range hydrogen bonding mediated effects in peptides: 15N NMR study of gramicidin S in water and organic solvents.
J. Am. Chem. Soc.
106:1939-1941[CrossRef].
|
| 40.
|
Malashkevich, V. N.,
D. C. Chan,
C. T. Chutkowski, and P. S. Kim.
1998.
Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides.
Proc. Natl. Acad. Sci. USA
95:9134-9139[Abstract/Free Full Text].
|
| 41.
|
Malashkevich, V. N.,
B. J. Schneider,
M. L. McNally,
M. A. Milhollen,
J. X. Pang, and P. S. Kim.
1999.
Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution.
Proc. Natl. Acad. Sci. USA
96:2662-2667[Abstract/Free Full Text].
|
| 42.
|
McInerney, T. L.,
W. El Ahmar,
B. E. Kemp, and P. Poumbourios.
1998.
Mutation-directed chemical cross-linking of human immunodeficiency virus type 1 gp41 oligomers.
J. Virol.
72:1523-1533[Abstract/Free Full Text].
|
| 43.
|
Norwood, T. J.,
J. Boyd,
J. E. Heritage,
N. Soffe, and I. D. Campbell.
1990.
Comparison of techniques for 1H-detected heteronuclear 1H-15N spectroscopy.
J. Magn. Reson.
87:488-501.
|
| 44.
|
Peisajovich, S. G.,
O. Samuel, and Y. Shai.
2000.
Paramyxovirus F1 protein has two fusion peptides: implications for the mechanism of membrane fusion.
J. Mol. Biol.
296:1353-1365[CrossRef][Medline].
|
| 45.
|
Piotto, M.,
V. Saudek, and V. Sklenar.
1992.
Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions.
J. Biomol. NMR
2:661-665[CrossRef][Medline].
|
| 46.
|
Rabenstein, M., and Y. K. Shin.
1995.
A peptide from the heptad repeat of human immunodeficiency virus gp41 shows both membrane binding and coiled-coil formation.
Biochemistry
34:13390-13397[CrossRef][Medline].
|
| 47.
|
Ralston, G. B.
1994.
The concentration dependence of the activity coefficient of the human spectrin heterodimer. A quantitative test of the Adams-Fujita approximation.
Biophys. Chem.
52:51-61[CrossRef][Medline].
|
| 48.
|
Rapaport, D.,
M. Ovadia, and Y. Shai.
1995.
A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses.
EMBO J.
14:5524-5531[Medline].
|
| 49.
|
Reitter, J. N.,
T. Sergel, and T. G. Morrison.
1995.
Mutational analysis of the leucine zipper motif in the Newcastle disease virus fusion protein.
J. Virol.
69:5995-6004[Abstract].
|
| 50.
|
Rimsky, L. T.,
D. C. Shugars, and T. J. Matthews.
1998.
Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.
J. Virol.
72:986-993[Abstract/Free Full Text].
|
| 51.
|
Rosenthal, P. B.,
X. Zhang,
F. Formanowski,
W. Fitz,
C. H. Wong,
H. Meier-Ewert,
J. J. Skehel, and D. C. Wiley.
1998.
Structure of the haemagglutinin-esterase-fusion glycoprotein of influenza C virus.
Nature
396:92-96[CrossRef][Medline].
|
| 52.
|
Russell, R.,
R. G. Paterson, and R. A. Lamb.
1994.
Studies with cross-linking reagents on the oligomeric form of the paramyxovirus fusion protein.
Virology
199:160-168[CrossRef][Medline].
|
| 53.
|
Shu, W.,
H. Ji, and M. Lu.
1999.
Trimerization specificity in HIV-1 gp41: analysis with a GCN4 leucine zipper model.
Biochemistry
38:5378-5385[CrossRef][Medline].
|
| 54.
|
Shugars, D. C.,
C. T. Wild,
T. K. Greenwell, and T. J. Matthews.
1996.
Biophysical characterization of recombinant proteins expressing the leucine zipper-like domain of the human immunodeficiency virus type 1 transmembrane protein gp41.
J. Virol.
70:2982-2991[Abstract].
|
| 55.
|
Tan, K.,
J. Liu,
J. Wang,
S. Shen, and M. Lu.
1997.
Atomic structure of a thermostable subdomain of HIV-1 gp41.
Proc. Natl. Acad. Sci. USA
94:12303-12308[Abstract/Free Full Text].
|
| 56.
|
Teng, M. N., and P. L. Collins.
1998.
Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles.
J. Virol.
72:5707-5716[Abstract/Free Full Text].
|
| 57.
|
Vuister, G., and A. Bax.
1993.
Quantitative J correlation: a new approach for measuring homonuclear three-bond J(HNH ) coupling constants in 15N-enriched proteins.
J. Amer. Chem. Soc.
115:7772-7777[CrossRef].
|
| 58.
|
Weissenhorn, W.,
A. Carfi,
K. H. Lee,
J. J. Skehel, and D. C. Wiley.
1998.
Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain.
Mol. Cell
2:605-616[CrossRef][Medline].
|
| 59.
|
Weissenhorn, W.,
A. Dessen,
S. C. Harrison,
J. J. Skehel, and D. C. Wiley.
1997.
Atomic structure of the ectodomain from HIV-1 gp41.
Nature
387:426-430[CrossRef][Medline].
|
| 60.
|
Whitehead, S. S.,
A. Bukreyev,
M. N. Teng,
C. Y. Firestone,
M. St. Claire,
W. R. Elkins,
P. L. Collins, and B. R. Murphy.
1999.
Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees.
J. Virol.
73:3438-3442[Abstract/Free Full Text].
|
| 61.
|
Wild, C.,
T. Oas,
C. McDanal,
D. Bolognesi, and T. Matthews.
1992.
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.
Proc. Natl. Acad. Sci. USA
89:10537-10541[Abstract/Free Full Text].
|
| 62.
|
Wild, C. T.,
D. C. Shugars,
T. K. Greenwell,
C. B. McDanal, and T. J. Matthews.
1994.
Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.
Proc. Natl. Acad. Sci. USA
91:9770-9774[Abstract/Free Full Text].
|
| 63.
|
Wilson, I.,
J. Skehel, and D. Wiley.
1981.
Structure of the heamagglutinin membrane glycoprotein of influenza at 3 Å resolution.
Nature
289:366-373[CrossRef][Medline].
|
| 64.
|
Wingfield, P. T.,
S. J. Stahl,
J. Kaufman,
A. Zlotnick,
C. C. Hyde,
A. M. Gronenborn, and G. M. Clore.
1997.
The extracellular domain of immunodeficiency virus gp41 protein: expression in Escherichia coli, purification, and crystallization.
Protein Sci.
6:1653-1660[Medline].
|
| 65.
|
Wolf, E.,
P. S. Kim, and B. Berger.
1997.
MultiCoil: a program for predicting two- and three-stranded coiled coils.
Protein Sci.
6:1179-1189[Medline].
|
| 66.
|
Yang, J.,
C.-S. Wu, and H. Martinez.
1986.
Calculation of protein conformation from circular dichroism.
Methods Enzymol.
130:208-269[Medline].
|
| 67.
|
Yao, Q., and R. W. Compans.
1996.
Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection.
Virology
223:103-112[CrossRef][Medline].
|
| 68.
|
Young, J. K.,
R. P. Hicks,
G. E. Wright, and T. G. Morrison.
1997.
Analysis of a peptide inhibitor of paramyxovirus (NDV) fusion using biological assays, NMR, and molecular modeling.
Virology
238:291-304[CrossRef][Medline].
|
| 69.
|
Young, J. K.,
D. Li,
M. C. Abramowitz, and T. G. Morrison.
1999.
Interaction of peptides with sequences from the Newcastle disease virus fusion protein heptad repeat regions.
J. Virol.
73:5945-5956[Abstract/Free Full Text].
|
Journal of Virology, July 2000, p. 5911-5920, Vol. 74, No. 13
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Bartoli, L., Fariselli, P., Krogh, A., Casadio, R.
(2009). CCHMM_PROF: a HMM-based coiled-coil predictor with evolutionary information. Bioinformatics
25: 2757-2763
[Abstract]
[Full Text]
-
Crim, R. L., Audet, S. A., Feldman, S. A., Mostowski, H. S., Beeler, J. A.
(2007). Identification of Linear Heparin-Binding Peptides Derived from Human Respiratory Syncytial Virus Fusion Glycoprotein That Inhibit Infectivity. J. Virol.
81: 261-271
[Abstract]
[Full Text]
-
Martin, D., Calder, L. J., Garcia-Barreno, B., Skehel, J. J., Melero, J. A.
(2006). Sequence elements of the fusion peptide of human respiratory syncytial virus fusion protein required for activity. J. Gen. Virol.
87: 1649-1658
[Abstract]
[Full Text]
-
McGinnes, L. W., Morrison, T. G.
(2006). Inhibition of Receptor Binding Stabilizes Newcastle Disease Virus HN and F Protein-Containing Complexes. J. Virol.
80: 2894-2903
[Abstract]
[Full Text]
-
Douglas, J. L., Panis, M. L., Ho, E., Lin, K.-Y., Krawczyk, S. H., Grant, D. M., Cai, R., Swaminathan, S., Chen, X., Cihlar, T.
(2005). Small Molecules VP-14637 and JNJ-2408068 Inhibit Respiratory Syncytial Virus Fusion by Similar Mechanisms. Antimicrob. Agents Chemother.
49: 2460-2466
[Abstract]
[Full Text]
-
West, D. S., Sheehan, M. S., Segeleon, P. K., Dutch, R. E.
(2005). Role of the Simian Virus 5 Fusion Protein N-Terminal Coiled-Coil Domain in Folding and Promotion of Membrane Fusion. J. Virol.
79: 1543-1551
[Abstract]
[Full Text]
-
Ruiz-Arguello, M. B., Martin, D., Wharton, S. A., Calder, L. J., Martin, S. R., Cano, O., Calero, M., Garcia-Barreno, B., Skehel, J. J., Melero, J. A.
(2004). Thermostability of the human respiratory syncytial virus fusion protein before and after activation: implications for the membrane-fusion mechanism. J. Gen. Virol.
85: 3677-3687
[Abstract]
[Full Text]
-
Cianci, C., Langley, D. R., Dischino, D. D., Sun, Y., Yu, K.-L., Stanley, A., Roach, J., Li, Z., Dalterio, R., Colonno, R., Meanwell, N. A., Krystal, M.
(2004). Targeting a binding pocket within the trimer-of-hairpins: Small-molecule inhibition of viral fusion. Proc. Natl. Acad. Sci. USA
101: 15046-15051
[Abstract]
[Full Text]
-
Tripet, B., Howard, M. W., Jobling, M., Holmes, R. K., Holmes, K. V., Hodges, R. S.
(2004). Structural Characterization of the SARS-Coronavirus Spike S Fusion Protein Core. J. Biol. Chem.
279: 20836-20849
[Abstract]
[Full Text]
-
Forzan, M., Wirblich, C., Roy, P.
(2004). A capsid protein of nonenveloped Bluetongue virus exhibits membrane fusion activity. Proc. Natl. Acad. Sci. USA
101: 2100-2105
[Abstract]
[Full Text]
-
Cianci, C., Yu, K.-L., Combrink, K., Sin, N., Pearce, B., Wang, A., Civiello, R., Voss, S., Luo, G., Kadow, K., Genovesi, E. V., Venables, B., Gulgeze, H., Trehan, A., James, J., Lamb, L., Medina, I., Roach, J., Yang, Z., Zadjura, L., Colonno, R., Clark, J., Meanwell, N., Krystal, M.
(2004). Orally Active Fusion Inhibitor of Respiratory Syncytial Virus. Antimicrob. Agents Chemother.
48: 413-422
[Abstract]
[Full Text]
-
Douglas, J. L., Panis, M. L., Ho, E., Lin, K.-Y., Krawczyk, S. H., Grant, D. M., Cai, R., Swaminathan, S., Cihlar, T.
(2003). Inhibition of Respiratory Syncytial Virus Fusion by the Small Molecule VP-14637 via Specific Interactions with F Protein. J. Virol.
77: 5054-5064
[Abstract]
[Full Text]
-
Plemper, R. K., Compans, R. W.
(2003). Mutations in the Putative HR-C Region of the Measles Virus F2 Glycoprotein Modulate Syncytium Formation. J. Virol.
77: 4181-4190
[Abstract]
[Full Text]
-
Huntley, C. C., Weiss, W. J., Gazumyan, A., Buklan, A., Feld, B., Hu, W., Jones, T. R., Murphy, T., Nikitenko, A. A., O'Hara, B., Prince, G., Quartuccio, S., Raifeld, Y. E., Wyde, P., O'Connell, J. F.
(2002). RFI-641, a Potent Respiratory Syncytial Virus Inhibitor. Antimicrob. Agents Chemother.
46: 841-847
[Abstract]
[Full Text]
-
Yu, M., Wang, E., Liu, Y., Cao, D., Jin, N., Zhang, C. W.-H., Bartlam, M., Rao, Z., Tien, P., Gao, G. F.
(2002). Six-helix bundle assembly and characterization of heptad repeat regions from the F protein of Newcastle disease virus. J. Gen. Virol.
83: 623-629
[Abstract]
[Full Text]
-
Rixon, H. W. McL., Brown, C., Brown, G., Sugrue, R. J.
(2002). Multiple glycosylated forms of the respiratory syncytial virus fusion protein are expressed in virus-infected cells. J. Gen. Virol.
83: 61-66
[Abstract]
[Full Text]
-
Tsurudome, M., Ito, M., Nishio, M., Kawano, M., Komada, H., Ito, Y.
(2001). Hemagglutinin-Neuraminidase-Independent Fusion Activity of Simian Virus 5 Fusion (F) Protein: Difference in Conformation between Fusogenic and Nonfusogenic F Proteins on the Cell Surface. J. Virol.
75: 8999-9009
[Abstract]
[Full Text]
-
Hassan, S. H., Wirblich, C., Forzan, M., Roy, P.
(2001). Expression and Functional Characterization of Bluetongue Virus VP5 Protein: Role in Cellular Permeabilization. J. Virol.
75: 8356-8367
[Abstract]
[Full Text]
-
Sergel, T. A., McGinnes, L. W., Morrison, T. G.
(2001). Mutations in the Fusion Peptide and Adjacent Heptad Repeat Inhibit Folding or Activity of the Newcastle Disease Virus Fusion Protein. J. Virol.
75: 7934-7943
[Abstract]
[Full Text]
-
Gonzalez-Reyes, L., Ruiz-Arguello, M. B., Garcia-Barreno, B., Calder, L., Lopez, J. A., Albar, J. P., Skehel, J. J., Wiley, D. C., Melero, J. A.
(2001). Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc. Natl. Acad. Sci. USA
10.1073/pnas.151098198v1
[Abstract]
[Full Text]
-
Zimmer, G., Trotz, I., Herrler, G.
(2001). N-Glycans of F Protein Differentially Affect Fusion Activity of Human Respiratory Syncytial Virus. J. Virol.
75: 4744-4751
[Abstract]
[Full Text]
-
Zhao, X., Singh, M., Malashkevich, V. N., Kim, P. S.
(2000). Structural characterization of the human respiratory syncytial virus fusion protein core. Proc. Natl. Acad. Sci. USA
10.1073/pnas.260499197v1
[Abstract]
[Full Text]
-
Gonzalez-Reyes, L., Ruiz-Arguello, M. B., Garcia-Barreno, B., Calder, L., Lopez, J. A., Albar, J. P., Skehel, J. J., Wiley, D. C., Melero, J. A.
(2001). Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc. Natl. Acad. Sci. USA
98: 9859-9864
[Abstract]
[Full Text]
-
Zhao, X., Singh, M., Malashkevich, V. N., Kim, P. S.
(2000). Structural characterization of the human respiratory syncytial virus fusion protein core. Proc. Natl. Acad. Sci. USA
97: 14172-14177
[Abstract]
[Full Text]